ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch

On August 3, ORIC Pharmaceuticals (NASDAQ: ORIC ) reported second-quarter results that showed a clinical-stage biotech converting years of early work into two separate late-stage bets at once. The company started Himalayas-1, a global Phase 3 trial of its lead prostate cancer drug rinzimetostat, while holding $387.6 million in cash and investments to fund the effort. That combination, a pivotal trial underway and years of runway behind it, is the whole story of the quarter.

Himalayas-1 is designed to enroll roughly 600 patients across more than 250 sites in 25 countries, randomizing them 1:1 to rinzimetostat plus darolutamide against a physician's choice of an androgen receptor inhibitor or docetaxel. The primary endpoint is radiographic progression-free survival, with overall survival tracked as the key secondary measure. ORIC finalized the protocol only after End-of-Phase 1 talks with the FDA and other global regulators, and it paired the launch with a supply deal with Bayer, which provides its approved drug NUBEQA at no cost for the trial. ORIC kept full global rights to rinzimetostat, so the arrangement adds a partner's drug to the combination without handing over any of the underlying asset.

Preclinical data presented at AACR gave a scientific rationale for the approach, showing that PRC2 inhibition curbs how prostate tumors adapt and helps sustain the benefit patients get from AR inhibition. The company's second program, enozertinib, is running four separate Phase 1b studies in EGFR-mutated lung cancer, covering exon 20 insertions and atypical mutations, both alone and paired with amivantamab or chemotherapy. Data from the atypical mutation study is scheduled for the ESMO Congress in October, with exon 20 monotherapy and combination results expected later in the year. ORIC says its cash position funds operations into the second half of 2028, which the company frames as carrying it past the first Himalayas-1 readout.

Running a 600-patient global trial costs money, and the expense lines show it. Research and development spending rose to $36.3 million for the quarter, up from $30.5 million a year earlier, an increase the company tied to rinzimetostat's advancement even as enozertinib costs eased on manufacturing and clinical timing. General and administrative costs crept up too, to $9.0 million from $8.5 million, on higher personnel and professional service costs. Add it up, and the net loss widened to $41.5 million for the quarter from $36.4 million a year ago, with the six-month loss reaching $77.3 million versus $66.4 million.